An eHealth App (CAPABLE) Providing Symptom Monitoring, Well-Being Interventions, and Educational Material for Patients With Melanoma Treated With Immune Checkpoint Inhibitors: Protocol for an Exploratory Intervention Trial (Preprint)-Reference-Cited by-同舟云学术

An eHealth App (CAPABLE) Providing Symptom Monitoring, Well-Being Interventions, and Educational Material for Patients With Melanoma Treated With Immune Checkpoint Inhibitors: Protocol for an Exploratory Intervention Trial (Preprint)

Published:2023-05-24 Issue: Volume: Page:
ISSN:
Container-title:
language:
Short-container-title:

Author:

Fraterman Itske^ORCID,Wollersheim Barbara M^ORCID,Tibollo Valentina^ORCID,Glaser Savannah Lucia Catherina^ORCID,Medlock Stephanie^ORCID,Cornet Ronald^ORCID,Gabetta Matteo^ORCID,Gisko Vitali^ORCID,Barkan Ella^ORCID,di Flora Nicola^ORCID,Glasspool David^ORCID,Kogan Alexandra^ORCID,Lanzola Giordano^ORCID,Leizer Roy^ORCID,Mallo Henk^ORCID,Ottaviano Manuel^ORCID,Peleg Mor^ORCID,van de Poll-Franse Lonneke V^ORCID,Veggiotti Nicole^ORCID,Śniatała Konrad^ORCID,Wilk Szymon^ORCID,Parimbelli Enea^ORCID,Quaglini Silvana^ORCID,Rizzo Mimma^ORCID,Locati Laura Deborah^ORCID,Boekhout Annelies^ORCID,Sacchi Lucia^ORCID,Wilgenhof Sofie^ORCID

Abstract

BACKGROUND

Since treatment with immune checkpoint inhibitors (ICIs) is becoming standard therapy for patients with high-risk and advanced melanoma, an increasing number of patients experience treatment-related adverse events such as fatigue. Until now, studies have demonstrated the benefits of using eHealth tools to provide either symptom monitoring or interventions to reduce treatment-related symptoms such as fatigue. However, an eHealth tool that facilitates the combination of both symptom monitoring and symptom management in patients with melanoma treated with ICIs is still needed.

OBJECTIVE

In this pilot study, we will explore the use of the CAPABLE (Cancer Patients Better Life Experience) app in providing symptom monitoring, education, and well-being interventions on health-related quality of life (HRQoL) outcomes such as fatigue and physical functioning, as well as patients’ acceptance and usability of using CAPABLE.

METHODS

This prospective, exploratory pilot study will examine changes in fatigue over time in 36 patients with stage III or IV melanoma during treatment with ICI using CAPABLE (a smartphone app and multisensory smartwatch). This cohort will be compared to a prospectively collected cohort of patients with melanoma treated with standard ICI therapy. CAPABLE will be used for a minimum of 3 and a maximum of 6 months. The primary endpoint in this study is the change in fatigue between baseline and 3 and 6 months after the start of treatment. Secondary end points include HRQoL outcomes, usability, and feasibility parameters.

RESULTS

Study inclusion started in April 2023 and is currently ongoing.

CONCLUSIONS

This pilot study will explore the effect, usability, and feasibility of CAPABLE in patients with melanoma during treatment with ICI. Adding the CAPABLE system to active treatment is hypothesized to decrease fatigue in patients with high-risk and advanced melanoma during treatment with ICIs compared to a control group receiving standard care. The Medical Ethics Committee NedMec (Amsterdam, The Netherlands) granted ethical approval for this study (reference number 22-981/NL81970.000.22).

CLINICALTRIAL

ClinicalTrials.gov NCT05827289; https://clinicaltrials.gov/study/NCT05827289

INTERNATIONAL REGISTERED REPORT

DERR1-10.2196/49252

Publisher

JMIR Publications Inc.

Reference60 articles.

1. Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

2. Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma

3. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

4. Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

5. An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors